TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15491704

Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 154
Study: 12929060

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping using a transparent cap
Number of subjects: 74

Group type: COMPARATOR
Intervention: Endoscopic hemoclipping without a transparent cap
Number of subjects: 74
Study: 9888867

Group type: EXPERIMENTAL
Intervention: 7 g/d omega-3 fatty acids for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 7 g/d omega-6 or omega-9 fatty acids for 4 weeks
Number of subjects: 28
Study: 7718754

Group type: EXPERIMENTAL
Intervention: Enalaprilat, 0.06 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 24
Study: 1851142

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2a interferon (Roferon‐A) at a dose of 5 MU/m2 S.C. three times a week and cisplatinum at dose levels of 15, 20, 25, 33, and 42 mg/m2/week given intravenously
Number of subjects: 18
Study: 6782467

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 12
Study: 30375028

Group type: EXPERIMENTAL
Intervention: Self-management intervention in primary health care (PHC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study: 29537978

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine (9.5 mg/10 cm daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral rivastigmine (6 mg twice daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral rivastigmine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 19
Study: 26507721

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 0
Study: 24326741

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 22748098

Group type: EXPERIMENTAL
Intervention: XELIRI-bevacizumab (irinotecan, capecitabine, bevacizumab, every 3 weeks)
Number of subjects: 285

Group type: COMPARATOR
Intervention: FOLFIRI-bevacizumab (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 285
Study: 21077306

Group type: EXPERIMENTAL
Intervention: BPB with 0.2% ropivacaine at an infusion rate of 6 ml x hr(‐1) (n = 12)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BPB with 0.2% ropivacaine at an infusion rate of 4 ml x hr(‐1) (n = 12)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no continuous BPB, n = 10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BPB with 0.2% ropivacaine at an infusion rate of 8 ml x hr(‐1) (n = 5)
Number of subjects: 39
Study: 18197883

Group type: EXPERIMENTAL
Intervention: Home-based behavioural training (BT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Waitlist-control group (WLC)
Number of subjects: 108
Study: 15906030

Group type: EXPERIMENTAL
Intervention: Three cycles of chemotherapy prior to surgery and three cycles after surgery (Group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Six cycles of chemotherapy prior to surgery (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (six cycles)
Number of subjects: 24
Study: 12923506

Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 215

Group type: COMPARATOR
Intervention: Twin-block appliance
Number of subjects: 215
Study: 10505539

Group type: EXPERIMENTAL
Intervention: Hirudin (0.4 mg/kg bolus, then 0.15 mg/kg per hour infusion)
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Heparin (5,000-U bolus, then 15-U/kg per hour infusion)
Number of subjects: 10141

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 10141
Study: 8853213

Group type: EXPERIMENTAL
Intervention: Amesergide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1346818

Group type: COMPARATOR
Intervention: BCG vaccine
Number of subjects: 29113

Group type: EXPERIMENTAL
Intervention: BCG plus 6 x 10(8) irradiated, autoclaved M leprae
Number of subjects: 29113

Group type: EXPERIMENTAL
Intervention: BCG plus M leprae
Number of subjects: 29113
Study: 6374402

Group type: EXPERIMENTAL
Intervention: Oral lithium started at the time of biopsy‐proven hypoplasia
Number of subjects: 35

Group type: COMPARATOR
Intervention: No lithium
Number of subjects: 35
Study: 30536081

Group type: EXPERIMENTAL
Intervention: Roflumilast 250 μg daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31256137

Group type: EXPERIMENTAL
Intervention: Therapeutic Motion Simulation (TMSim)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TMSim + WBV
Number of subjects: 120
Study: 30239794

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1778

Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 1778
Study: 24473106

Group type: EXPERIMENTAL
Intervention: Caring letters intervention
Number of subjects: 0
Study: 23137494

Group type: EXPERIMENTAL
Intervention: Losmapimod (GW856553)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 20485147

Group type: EXPERIMENTAL
Intervention: Warmed (37 degrees C), humidified (98% RH) insufflation carbon dioxide
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard gas (19 degrees C, 0% RH)
Number of subjects: 82
Study: 18556964

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dosage of 0.067 mg/kg/day
Number of subjects: 0
Study: 16087818

Group type: EXPERIMENTAL
Intervention: Full starting dose of levothyroxine (1.6 mug/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low starting dose of levothyroxine (25 mug, increased every 4 weeks)
Number of subjects: 75
Study: 12452231

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg and droperidol 0.0625 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Morphine 1 mg
Number of subjects: 94
Study: 10358538

Group type: EXPERIMENTAL
Intervention: Standardised protocol administered by senior nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7807658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE), 0.625 mg/d
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo
Number of subjects: 875
Study: 8369511

Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone, 60 mg/day for 7 days, followed by tapering over 14 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 23
Study: 2947465

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 261

Group type: COMPARATOR
Intervention: metaproterenol
Number of subjects: 261
Study: 29792226

Group type: EXPERIMENTAL
Intervention: Tree Theme Method® (TTM)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Regular occupational therapy
Number of subjects: 118
Study: 27016875

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) integrity
Number of subjects: 15
Study: 25818388

Group type: EXPERIMENTAL
Intervention: Bofu-tsusho-san (BOF)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional control therapy
Number of subjects: 107
Study: 22684431

Group type: EXPERIMENTAL
Intervention: 10 mg/kg abatacept plus MTX
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 2 mg/kg abatacept plus MTX
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 195
Study: 21868617

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 5061

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 5061

Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 5061

Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count
Number of subjects: 5061
Study: 19933725

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 19
Study: 16800349

Group type: EXPERIMENTAL
Intervention: ICL670 (deferasirox) at a dose of 20 to 40 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICL670 (deferasirox)
Number of subjects: 0
Study: 15138373

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (manual techniques including parietal, visceral, and craniosacral techniques)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Orthopedic treatment (chiropractic techniques, antiphlogistics, and cortison injections)
Number of subjects: 53
Study: 11755325

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 9655732

Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg twice daily (BDP400+salm)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: beclomethasone 200 microg twice daily (BDP800)
Number of subjects: 177

Group type: COMPARATOR
Intervention: placebo (BDP400) in addition to beclomethasone 200 microg twice daily
Number of subjects: 177
Study: 8043993

Group type: COMPARATOR
Intervention: Enflurane anesthesia
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia supplemented by TAES with HANS at Hegu, Yuyao and Fengchi points
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia supplemented by TAES and scalp infiltration with 0.5% procaine
Number of subjects: 110
Study: 2899988

Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Atracurium 0.4 mg/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 205
Study: 29266792

Group type: EXPERIMENTAL
Intervention: Innovative self-management intervention for 4 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine hospital care (Control)
Number of subjects: 112
Study: 27312053

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin (25 mg/m² on days 1 and 8), etoposide (60 mg/m² on days 1-3), and irinotecan (90 mg/m² on day 8) for five 2-week courses.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Topotecan (1.0 mg/m² on days 1-5, every 3 weeks) for four courses.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Topotecan group
Number of subjects: 180
Study: 25284739

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 20636485

Group type: EXPERIMENTAL
Intervention: l‐NMMA (NO synthase inhibitor)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phenylephrine (α‐receptor agonist)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20178604

Group type: EXPERIMENTAL
Intervention: Bright light therapy (approximately 10,000 lux for two half-hour sessions daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (approximately 300 lux for two half-hour sessions daily)
Number of subjects: 0
Study: 18502107

Group type: EXPERIMENTAL
Intervention: Lignan complex (500 mg/d of secoisolariciresinol diglucoside)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (low-fat muffin without lignan complex)
Number of subjects: 22
Study: 15918387

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g + Ketoprofen 100 mg
Number of subjects: 97
Study: 12686673

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 23
Study: 10085472

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: melatonin (various doses)
Number of subjects: 14
Study: 2488185

Group type: COMPARATOR
Intervention: i.p. urokinase (5000 i.u.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CAPD catheter replacement
Number of subjects: 37
Study: 884446

Group type: EXPERIMENTAL
Intervention: Naloxone 200 microgram
Number of subjects: 30
Study: 30993660

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 99
Study: 31077798

Group type: EXPERIMENTAL
Intervention: AOMI (Action Observation and Motor Imagery) for 10 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AOMI+PAIN (AOMI during hypertonic saline injection)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PAIN (rest for 10 minutes after hypertonic saline injection)
Number of subjects: 12
Study: 27471815

Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 2 weeks (120 Q2W)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 4 weeks (120 Q4W)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo every 2 weeks (placebo Q2W)
Number of subjects: 45
Study: 25816720

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 714

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 714
Study: 24186620

Group type: EXPERIMENTAL
Intervention: Mepilex Lite dressings
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study: 20619600

Group type: EXPERIMENTAL
Intervention: T-tube (TT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pressure support (PS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Harris-Benedict (HB) equation without activity factor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Harris-Benedict (HB) equation with activity factor
Number of subjects: 40
Study: 19733721

Group type: EXPERIMENTAL
Intervention: Naproxcinod 750 mg twice daily
Number of subjects: 916

Group type: COMPARATOR
Intervention: Naproxcinod 750 mg
Number of subjects: 916

Group type: COMPARATOR
Intervention: Naproxcinod 375 mg
Number of subjects: 916

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 916
Study: 17531690

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime prophylaxis at 1 mg in 0.1 mL normal saline
Number of subjects: 16603

Group type: EXPERIMENTAL
Intervention: Clear corneal incisions (CCIs)
Number of subjects: 16603

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (IOL) optic material
Number of subjects: 16603

Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 16603

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 16603
Study: 15262827

Group type: EXPERIMENTAL
Intervention: Aprotinin (2x10(6) KIU in pump prime, 2x10(6) KIU loading dose, followed by 0.5x10(6) KIU/h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30
Study: 12214358

Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Simple advice
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 9850898

Group type: EXPERIMENTAL
Intervention: Topical tetracaine 0.5% plus intracameral lidocaine 1%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Topical tetracaine 0.5% plus intracameral BSS
Number of subjects: 59
Study: 7978091

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: oCRH (1 microgram/kg)
Number of subjects: 23
Study: 3377945

Group type: EXPERIMENTAL
Intervention: pethidine 1 mg kg‐1 i.v.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: pethidine 1 mg kg‐1 i.m.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: pethidine 1 mg kg‐1 rectally
Number of subjects: 25
Study: 380947

Group type: COMPARATOR
Intervention: Partial closure of the perineal wound and cigarette drainage of the pelvic space (Group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Complete suture of the perineal wound and suction drainage of the pelvic space (Group B)
Number of subjects: 65
Study: 31806235

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 62
Study: 28460544

Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early low dose aprotinin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Late low dose aprotinin
Number of subjects: 40

Group type: COMPARATOR
Intervention: No aprotinin (control)
Number of subjects: 40
Study: 25441397

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study: 24118053

Group type: EXPERIMENTAL
Intervention: Cold dry air provocation (CDA) in AR patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold dry air provocation (CDA) in NAR patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold dry air provocation (CDA) in healthy controls
Number of subjects: 0
Study: 22692637

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle (ILS) program
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 850 mg twice daily
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3234
Study: 20110592

Group type: EXPERIMENTAL
Intervention: Complex antioxidant blend (active treatment) for four months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo treatment (identical gel and bottle) for four months
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Complex antioxidant blend (active treatment)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 113
Study: 17395870

Group type: EXPERIMENTAL
Intervention: Endovascular coiling (EVT)
Number of subjects: 2108

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2108
Study: 16136166

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 285

Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Chemotherapy (without donor)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Cytogenetic features (favorable, intermediate, unfavorable)
Number of subjects: 285
Study: 11903940

Group type: EXPERIMENTAL
Intervention: Single Shot (SS) technique with 0.25 ml x kg(‐1) of 0.25% bupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Double Shot (DS) technique with one-third of total dose of bupivacaine given as SS and remaining two-thirds deposited above and lateral to mid‐inguinal point
Number of subjects: 90
Study: 10206309

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 4400

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus chemotherapy
Number of subjects: 4400
Study: 10829909

Group type: EXPERIMENTAL
Intervention: Hexosaminidase A and B deficiency assessment
Number of subjects: 449
Study: 2116082

Group type: EXPERIMENTAL
Intervention: CA 300 mg alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CA 200 mg + mitomycin C (MMC) 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CA 180 mg + adriamycin (ADM) 20 mg
Number of subjects: 60
Study: 387225

Group type: EXPERIMENTAL
Intervention: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 30 mg/m2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 100 mg/m2
Number of subjects: 140

Group type: COMPARATOR
Intervention: Combination of chlorambucil and cis‐platinum (regimen B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination of chlorambucil, cis‐platinum, and Adriamycin (regimen C)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both regimens (B and C)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: cis‐platinum
Number of subjects: 140
Study: 31222188

Group type: EXPERIMENTAL
Intervention: Unattended office blood pressure (UBP)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Conventional attended office blood pressure (CBP)
Number of subjects: 308
Study: 25213116

Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-preferred treatment
Number of subjects: 0
Study: 25066012

Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 400

Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 400
Study: 23363492

Group type: EXPERIMENTAL
Intervention: Filgrastim 300 micrograms/day for 7 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 21876296

Group type: EXPERIMENTAL
Intervention: Stretching device (resting hand splint, finger stretcher, and frame) used for 20 minutes per session, 2 sessions/day, 6 days/week for 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 21
Study: 19818599

Group type: EXPERIMENTAL
Intervention: STANDARD (n=279)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: STANDARD (n=373)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: TAILORED (n=364)
Number of subjects: 1016